Bio-Rad Laboratories has announced the launch of the Bio-Plex Pro Human IgA and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens.
A new study has revealed key insights into the natural human antiviral defences against SARS-CoV-2, the virus that causes COVID-19.
Salutaris People, a British healthcare and testing company, has unveiled a brand new SARS-CoV-2 testing laboratory at Liverpool John Lennon Airport.
Researchers at the University of Oxford are seeking NHSX funding for an artificial intelligence (AI) SARS-CoV-2 screening test.
The SARS-CoV-2 pandemic has focused everyone’s attention on the hidden world of viruses. The emergence of new variants, such as Beta and Delta, affects everyone: some variants spread more quickly and some are less affected by vaccines. But why?
Scientists at Children’s Hospital Los Angeles have been paying close attention to the behaviour of SARS-CoV-2 since the beginning of the pandemic, and have read the genetic sequence of the virus from every positive sample to identify mutations.
Stago has developed Asserachrom HPIA-IgG, a highly sensitive and specific ELISA for detecting anti-heparin-PF4 IgG antibodies, which has recently found application in the diagnosis of VITT.
The University of Lincoln in the UK, alongside five other British universities, will work on potentially ground-breaking research commissioned by the National Institute for Health Research (NIHR) to understand and tackle Long Covid.
Biotage is one of the few companies offering a complete solution and ready-to-go off-the-shelf products for the purification of large-scale lipids, used in mRNA vaccine development and production.
South Korea’s response to the pandemic has been praised, achieving success through rigorous preparation and rapid response, attributed to decisive government action, aggressive track-and-trace policies and almost immediate access to PCR tests.
BD and CerTest Biotec have announced the CE mark for a molecular test that can detect and distinguish between the Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) SARS-CoV-2 variants.
Owlstone Medical has announced the publication of a study in Nature Scientific Reports that investigates the performance of filters in face masks for supporting the detection of SARS-CoV-2 as an alternative to nasopharyngeal swabs (NPS).
Bio-Rad Laboratories has launched its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit, a sensitive, accurate and cost-effective tool used to detect SARS-CoV-2 in a community’s wastewater.
PhoenixSoft has developed a series of COVID-19 dashboards for Hampshire Hospitals NHS Foundation Trust (HHFT), which runs Basingstoke and North Hampshire Hospital, Royal Hampshire County Hospital, in Winchester, and Andover War Memorial Hospital.
A study has shown that the Avacta Group AffiDX antigen lateral-flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples, and outperformed two lateral-flow antigen tests that are commercially available in Europe.
Research published in the Journal of General Virology has identified missed cases of SARS-CoV-2 by retrospective testing of throat swabs.
Avacta Group has received notice of registration of its AffiDX SARS-CoV-2 antigen lateral-flow test in the EU, allowing the company to place the product on the market in all 27 countries of the EU for professional use.
Roche has received CE marking for its SARS-CoV-2 Antigen Self Test Nasal for at-home testing. The test will be available in countries accepting the CE mark through pharmacies and other locations, in packs of five tests.
Avacta Group has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed registration of the AffiDX SARS-CoV-2 antigen lateral-flow test, so it can place the product on the market in the UK for professional use.